https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46765 Wed 24 Apr 2024 10:05:04 AEST ]]> Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35202 Wed 23 Feb 2022 16:07:13 AEDT ]]> Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48609 Wed 22 Mar 2023 09:00:58 AEDT ]]> The effect of maternal immune activation and adolescent cannabinoid exposure on behaviour, neurophysiology and cognition in a rodent model of schizophrenia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38769 Wed 20 Mar 2024 15:52:14 AEDT ]]> Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29481 n = 144, 71%), followed by mouth spray (n = 84, 42%) and vaporiser (n = 83, 41%). Explanations for preferences (n = 134) most commonly cited convenience (n = 66; 49%). A total of 82% (n = 168) of respondents indicated that they had no trial-related concerns, but a small number volunteered concerns about adverse effects (n= 14) or wanted more information/advice (n = 8). Six respondents volunteered a belief that cannabis might cure cancer, while two wanted assurance of efficacy before participating in a trial. Conclusion: Justification of modes other than tablets/capsules and variable understanding about cannabis and trials will need addressing in trial-related information to optimise recruitment and ensure that consent is properly informed.]]> Wed 17 Nov 2021 16:32:30 AEDT ]]> From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52453 Wed 11 Oct 2023 15:07:47 AEDT ]]> Functional and structural brain imaging correlates of cannabis use in young people with schizophrenia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21989 Wed 11 Apr 2018 15:53:12 AEST ]]> Measuring change in cannabis use https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27247 Wed 11 Apr 2018 14:43:09 AEST ]]> Comorbid tobacco and other substance use and symptoms of anxiety and depression among hospitalised orthopaedic trauma patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35788 2 tests. Multivariate logistic regression explored variables related to tobacco smoking. Results: Eight hundred nineteen patients participated. Over one-fifth (21.8%) identified as a current smoker, half (51.8%) reported consuming alcohol at hazardous levels in the last 12 months, and about 10% stated that they had used cannabis in the last 30 days (9.7%), or experienced symptoms of either anxiety (12.4%), or depression (12.9%) in the last two weeks. Over one-fifth of current tobacco smokers (21.8%) reported drinking heavily in the last 12 months and using cannabis recently. Males, with a lower educational attainment, who were unmarried, had used cannabis recently, and report drinking heavily were more likely to be current smokers. Conclusions: Health behaviour interventions addressing comorbidities are warranted among the orthopaedic trauma population given the high rate of comorbidity and impact these may have on recovery.]]> Tue 26 Nov 2019 15:16:09 AEDT ]]> The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39851 .05). Objective sleep onset latency increased from the Baseline to the Treatment phase in the control (stretching) group (p = .042). In contrast, the Cycling group exhibited improvements in sleep duration (p = .008) and sleep efficiency (p = .023) during the Treatment phase compared to the Baseline phase. Cycling also increased sleep duration (p = .005), decreased average wake bout (p = .040) and tended to increase sleep efficiency (p = .051) compared to stretching during the Treatment phase. Subjective sleep quality ratings did not differ between groups (p > .10). These preliminary findings suggest that moderate-intensity aerobic exercise may attenuate the sleep disturbances associated with cannabis withdrawal.]]> Tue 26 Jul 2022 09:52:23 AEST ]]> It's worth a try: the treatment experiences of rural and urban participants in a randomized controlled trial of computerized psychological treatment for comorbid depression and alcohol/other drug use https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13844 Tue 24 Aug 2021 14:32:42 AEST ]]> Quik Fix: A randomised controlled trial of an enhanced brief motivational interviewing (BMI) intervention for alcohol/cannabis and psychological distress in young people https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13832 Tue 24 Aug 2021 14:29:22 AEST ]]> Perceived risk associated with tobacco, alcohol and cannabis use among people with and without psychotic disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13822 Tue 24 Aug 2021 14:27:22 AEST ]]> Reasons for substance use among people with psychotic disorders: method triangulation approach https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13821 Tue 24 Aug 2021 14:26:14 AEST ]]> Preliminary outcomes of a computerized CBT/MET intervention for depressed cannabis users in psychiatry care https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36663 Tue 23 Jun 2020 11:12:42 AEST ]]> Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38188 Tue 10 Aug 2021 15:11:51 AEST ]]> Cannabis, from plant to pill https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33603 Tue 03 Sep 2019 17:58:42 AEST ]]> The Effect of Schizophrenia Risk Factors On Mismatch Responses in a Rat Model https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50563 Tue 01 Aug 2023 10:18:31 AEST ]]> Do clinicians ask pregnant women about exposures to tobacco and cannabis smoking, second-hand-smoke and e-cigarettes? An Australian national cross-sectional survey https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31142 Thu 31 May 2018 11:46:47 AEST ]]> A simple isocratic HPLC method for the quantitation of 17 cannabinoids https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40111 Thu 28 Jul 2022 15:41:22 AEST ]]> Social anxiety, cannabis use motives, and social context’s impact on willingness to use cannabis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39679 Thu 28 Jul 2022 15:31:21 AEST ]]> Media reporting on alcohol and other drugs in Australia and the Mindframe guidelines: Baseline data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52652 Thu 19 Oct 2023 15:25:11 AEDT ]]> Pharmacokinetics of cannabis in cancer cachexia-anorexia syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29956 Thu 17 Feb 2022 09:29:58 AEDT ]]> Attitudes and perceptions regarding tobacco, alcohol or cannabis use among people with and without mental disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12035 Thu 11 Jul 2019 12:28:17 AEST ]]> Post-Harvest Operations to Generate High-Quality Medicinal Cannabis Products: A Systemic Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48153 Thu 09 Mar 2023 09:37:44 AEDT ]]> The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47934 Thu 09 Feb 2023 15:43:56 AEDT ]]> A Comprehensive Review on the Techniques for Extraction of Bioactive Compounds from Medicinal Cannabis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50589 Sun 30 Jul 2023 15:16:38 AEST ]]> Reasons for substance use among people with mental disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13767 Sat 24 Mar 2018 10:40:42 AEDT ]]> Cannabis and mental health: management in primary care https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11178 Sat 24 Mar 2018 10:31:47 AEDT ]]> Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7880 Sat 24 Mar 2018 08:41:35 AEDT ]]> An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9352 Sat 24 Mar 2018 08:36:34 AEDT ]]> From comorbidity to multiple health behaviour change https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15600 Sat 24 Mar 2018 08:22:55 AEDT ]]> Attitudes and perceptions towards substances among people with mental disorders: a systematic review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13818 Sat 24 Mar 2018 08:22:46 AEDT ]]> Chronic effects of cannabis use on the auditory mismatch negativity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19080 Sat 24 Mar 2018 08:05:20 AEDT ]]> Chronic effects of cannabis on sensory gating https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19068 Sat 24 Mar 2018 08:05:19 AEDT ]]> Web-based screening and brief intervention for student marijuana use in a university health center: Pilot study to examine the implementation of eCHECKUP TO GO in different contexts https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18306 Sat 24 Mar 2018 08:04:40 AEDT ]]> Cannabis, cannabinoids and schizophrenia: integration of the evidence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5100 Sat 24 Mar 2018 07:48:48 AEDT ]]> Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47 Sat 24 Mar 2018 07:42:00 AEDT ]]> Prescribe with caution: the response of Canada's medical regulatory authorities to the therapeutic use of cannabis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30116 Sat 24 Mar 2018 07:37:56 AEDT ]]> Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28421 Sat 24 Mar 2018 07:29:05 AEDT ]]> Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23512 Sat 24 Mar 2018 07:17:17 AEDT ]]> Internet-delivered tobacco treatment for people using cannabis: a randomized trial in two Australian cannabis clinics https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40382 internet-based Healthy Lifestyle Program (iHeLP; 4 modules). It was hypothesized that iHeLP completion would be associated with decreases in tobacco use and improved quality of life (QoL) and psychological health. It was also hypothesized that iHeLP completion would be higher in those who additionally received telephone support. Given that iHeLP aimed to improve healthy lifestyle behaviors, it was also hypothesized that there would be reductions in cannabis use. Methods: A total of 13 smokers seeking treatment for cannabis use were randomly allocated to iHeLP alone or iHeLP plus telephone support. Participants were engaged in iHeLP over 8 weeks and completed a 12-week follow-up assessment. Results: Results from 10 participants who completed the follow-up indicated that the acceptability of iHeLP was high-very high in terms of general satisfaction, appropriateness of services, effectiveness, and met need. Additional telephone support increased modal module completion rates for iHeLP from 0 to 2 but did not provide any other significant advantages over iHeLP alone in terms of cannabis use, tobacco use, QoL, or psychological health. Participants in the iHeLP-alone condition (n=4) reported a mean reduction of 5.5 (SD 9.00) tobacco cigarettes per day between baseline and follow-up, with a concomitant mean reduction in expired carbon monoxide (CO) of 5.5 parts per million (ppm, SD 6.91). The iHeLP plus telephone support group (n=6) reported a mean reduction of 1.13 (SD 4.88) tobacco cigarettes per day and a mean reduction of 9.337 ppm of expired CO (SD 5.65). A urinalysis indicated that abstinence from cannabis was achieved by 2 participants in the iHeLP-alone group and three participants in the iHeLP plus telephone support group. Between baseline and follow-up assessments, iHeLP-alone participants reported a mean reduction in days of use of cannabis in the prior month of 6.17 days (SD 13.30). The average reduction in the number of days of cannabis use for the iHeLP plus telephone support group was also 6.17 days (SD 13.59). Conclusions: Despite the small sample size, this study provides preliminary support for the use of internet-delivered, tobacco-focused interventions in tobacco smokers seeking treatment for cannabis use.]]> Mon 11 Jul 2022 10:53:44 AEST ]]> A randomised controlled trial of vaporised Δ⁹-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36056 Mon 03 Feb 2020 11:52:08 AEDT ]]> Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20285 Fri 28 Aug 2015 08:51:23 AEST ]]> Gaps in predicting clinical doses for cannabinoids therapy: overview of issues for pharmacokinetics and pharmacodynamics modelling https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46543 Fri 25 Nov 2022 11:12:36 AEDT ]]> Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48101 Fri 24 Feb 2023 15:38:03 AEDT ]]> Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44120 Fri 07 Oct 2022 14:26:41 AEDT ]]> Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32031 Fri 01 Apr 2022 09:23:38 AEDT ]]>